



BETA DRUGS LIMITED

BDL/PKL/SEC/2022

2nd March, 2022

To,
National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra East
Mumbai 400051

Script:-BETA

Dear Sir,

Sub.: Clarification for announcement submitted dated 2nd February, 2022

Pursuant to clarification sought by NSE vide email dated 07.02.2022, we hereby inform that BDL is expected to launch Carfilzomib in this month i.e. March'22 and Rucaparib in Qtr 1 of FY 23. As of now, company will cater both the molecules in domestic market and will explore possibility of launch in International market from FY 24 onwards. Currently BDL supplies its Oncological range to over 15 countries which includes region like Africa, Latin America, CIS and South East Asia and will initiate registration of both these molecules in existing countries as a 1st step in International market.

This is for your information and appropriate dissemination.

Thanking You

Your's faithfully

For Beta Drugs Limited



Rajni Brar

Company Secretary

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com